| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by operating activities | 12,825 | 9,133 |
| Purchases of leasehold improvements and equipment | 191 | 167 |
| Proceeds from the sale of leasehold improvements and equipment, net | 0 | - |
| Net cash used in investing activities | -191 | -167 |
| Proceeds from exercise of stock options | 7,018 | 6,866 |
| Payment of debt issuance costs | 12 | 12 |
| Principal payments on finance leases | 10 | 6 |
| Net cash provided by financing activities | 6,996 | 6,848 |
| Net increase in cash and cash equivalents | 19,630 | 15,814 |
| Cash and cash equivalents at beginning of period | 44,660 | - |
| Cash and cash equivalents at end of period | 64,290 | - |
Niagen Bioscience, Inc. (NAGE)
Niagen Bioscience, Inc. (NAGE)